1418200-58-4

1418200-58-4 structure

1418200-58-4 structure

Name: Sofituzumab Vedotin
Chemical Name: Sofituzumab Vedotin
CAS Number: 1418200-58-4
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-04-08 15:38:46
Modify Date: 2024-04-07 02:47:25
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].

Name	Sofituzumab Vedotin

Description	Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].
Related Catalog	Research Areas >> Cancer
References	[1]. Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel). 2020 Aug 9;12(8):2223. [2]. Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130. [3]. Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924-32.

No Any Chemical & Physical Properties